Targeted Therapy in Melanoma and Mechanisms of Resistance

The common mutation BRAFV600 in primary melanomas activates the mitogen-activated protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the introduction of proto-oncogene B-Raf (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors (BRAFi and MEKi) was a breakthrou...

Descripción completa

Detalles Bibliográficos
Autores principales: Czarnecka, Anna M., Bartnik, Ewa, Fiedorowicz, Michał, Rutkowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369697/
https://www.ncbi.nlm.nih.gov/pubmed/32605090
http://dx.doi.org/10.3390/ijms21134576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369697/
https://www.ncbi.nlm.nih.gov/pubmed/32605090
http://dx.doi.org/10.3390/ijms21134576

Ejemplares similares